CD4+ is associated with COVID-19-infected pneumonia patient recovery and recurrence
Coronavirus Disease 2019 (COVID-19)–infected pneumonia (CDIP) occurred in Wuhan, China, in December 2019, from where the disease has spread all over the world. Although the morbidity and mortality in China have been effectively controlled, the number of cases has increased rapidly in countries other than China. Here we report the epidemiological and clinical characteristics of 7 CDIP patients. We found that similar with the throat swabs, sputum induction still has a false negative rate. In addition, CD4+ count rise occurred before the disease remission, and decreased CD4+ count may be the cause of virus recurrence. These imply that CD4+ count could be a marker for recover and reinfection. Notably, we tentatively speculate that CD4+ plays a key role in the body's resistance to the COVID-19 attack on lung tissue.
Figure 1
Posted 10 Jun, 2020
CD4+ is associated with COVID-19-infected pneumonia patient recovery and recurrence
Posted 10 Jun, 2020
Coronavirus Disease 2019 (COVID-19)–infected pneumonia (CDIP) occurred in Wuhan, China, in December 2019, from where the disease has spread all over the world. Although the morbidity and mortality in China have been effectively controlled, the number of cases has increased rapidly in countries other than China. Here we report the epidemiological and clinical characteristics of 7 CDIP patients. We found that similar with the throat swabs, sputum induction still has a false negative rate. In addition, CD4+ count rise occurred before the disease remission, and decreased CD4+ count may be the cause of virus recurrence. These imply that CD4+ count could be a marker for recover and reinfection. Notably, we tentatively speculate that CD4+ plays a key role in the body's resistance to the COVID-19 attack on lung tissue.
Figure 1